ESSA Pharma Inc. has entered into a Business Combination Agreement with XenoTherapeutics, Inc. on July 13, 2025, for Xeno to acquire ESSA's common shares; shareholders are expected to receive approximately $1.91 per share in cash plus a contingent value right. The deal requires shareholder approval and is subject to various closing conditions.